Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLYPse: Encorafenib + Cetuximab + FOLFIRI in BRAF V600E mCRC
NCT06640166Phase 2Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, KL-140 in metastatic colorectal cancer (mCRC), sponsored by Policlinico Gemelli. Started Jun 2024; status: recruiting.
02
Drugs
encorafenibKL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06640166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640166.